# Signals Article on Putative Target P05455 for Systemic Lupus Erythematosus
Background
The protein encoded by the UniProt entry P05455, also known as the putative target candidate, has emerged as a potential therapeutic target in the context of systemic lupus erythematosus (SLE). SLE is a complex autoimmune disease characterized by dysregulated immune responses leading to multi-organ damage. The identification of P05455 as a candidate warrants further investigation due to its presence in expression-profiling studies, suggesting a possible role in the pathogenesis of SLE. However, the absence of any registered Phase 1 or higher clinical programs targeting this protein indicates a gap in the exploration of its therapeutic potential.Data-mining rationale
The rationale for identifying P05455 stems from a comprehensive analysis of publicly available data. By cross-referencing UniProt's reviewed human entries associated with "systemic lupus erythematosus" against 244 microarray datasets in the NCBI Gene Expression Omnibus (GEO), we identified P05455 as a candidate of interest. Notably, this protein appeared in multiple expression-profiling studies (GDS:200315667, GDS:200318067, GDS:200277400, GDS:200240466, GDS:200240335), yet no corresponding clinical development has been documented. This discrepancy highlights the need for further investigation into its potential role in SLE.Why prior analyses may have missed this
Prior analyses may have overlooked P05455 due to the limitations of earlier statistical methodologies employed in the evaluation of microarray data. Many of the GEO datasets utilized predate the adoption of modern empirical-Bayes statistical methods, such as the limma package, which provides more robust handling of multiple testing corrections. As a result, the expression profiles of P05455 may not have been accurately assessed, leading to its exclusion from consideration as a viable therapeutic target.Reasoning for further validation
To substantiate the potential role of P05455 in SLE, several experimental approaches are warranted: 1. **Re-analysis of GEO datasets**: Employ the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set at < 0.05 to identify differentially expressed genes, including P05455, in the matched GEO datasets. 2. **Validation of expression levels**: Conduct quantitative PCR (qPCR) to validate the expression levels of P05455 and other top differentially expressed genes in an independent cohort of SLE patients. 3. **Tissue specificity assessment**: Utilize resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine the tissue specificity of P05455 expression, which may provide insights into its functional relevance in SLE. 4. **Pathway context analysis**: Implement tools like STRING or OmniPath to explore the biological pathways associated with P05455, potentially elucidating its role in the disease mechanism. 5. **Druggability assessment**: If validation of P05455's involvement in SLE is achieved, assess its druggability using databases such as DGIdb and ChEMBL to evaluate the feasibility of developing therapeutic agents targeting this candidate.References
- UniProt: P05455
- UniProt: P12956
- UniProt: P13010
- UniProt: P16410
- UniProt: P0C0L5
- GEO Accession: GDS:200315667
- GEO Accession: GDS:200318067
- GEO Accession: GDS:200277400
- GEO Accession: GDS:200240466
- GEO Accession: GDS:200240335
*This article is an AI-curated commentary and has not undergone peer review.*